AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 25, 2003
REGISTRATION STATEMENT NO. 33-___________
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------------------
FORM S-3
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
------------------------------------
LIGAND PHARMACEUTICALS INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
DELAWARE
(State or Other Jurisdiction of Incorporation or Organization)
77-0160744
(I.R.S. Employer Identification Number)
------------------------------------
10275 Science Center Drive, San Diego, California 92121-1117
(858) 550-7500
(Address, Including Zip Code, and Telephone Number, Including Area Code, of
Registrant's Principal Executive Offices)
------------------------------------
David E. Robinson
President and Chief Executive Officer
LIGAND PHARMACEUTICALS INCORPORATED
10275 Science Center Drive, San Diego, California 92121-1117 (858) 550-7500
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code,
of Agent for Service)
------------------------------------
Copies to:
Faye H. Russell, Esq.
CLIFFORD CHANCE US LLP
3811 Valley Centre Drive, Suite 200
San Diego, California 92130
(858) 720-3500
------------------------------------
Approximate date of commencement of proposed sale to the public: From time
to time after the effective date of this registration statement.
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box: [ ]
If any of the securities being registered on this form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box: [x]
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective
registration statement for the same offering: [ ]
If this form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering: [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box: [ ]
CALCULATION OF REGISTRATION FEE
====================================== =============== ====================== ========================== =================
PROPOSED MAXIMUM
TITLE OF SHARES AMOUNT TO BE AGGREGATE OFFERING PROPOSED MAXIMUM AMOUNT OF
TO BE REGISTERED REGISTERED (1) PRICE PER SHARE (2) AGGREGATE OFFERING REGISTRATION FEE
PRICE(2)
-------------------------------------- --------------- ---------------------- -------------------------- -----------------
Common Stock, par value $.001 per 5,835,771 $14.78 $86,252,695.38 $6,977.84
share
====================================== =============== ====================== ========================== =================
(1) This registration statement shall also cover any additional shares of
common stock which become issuable in connection with the shares registered
for sale hereby as a result of any stock dividend, stock split,
recapitalization or other similar transaction effected without the receipt
of consideration which results in an increase in the number of the
Registrant's outstanding shares of common stock.
(2) Estimated solely for the purpose of determining the registration fee and
computed pursuant to Rule 457(c) based on the average of the high and low
sales prices per share of the common stock on July 24, 2003 as reported on
The Nasdaq Stock Market.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT
SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SEC, ACTING PURSUANT TO SAID SECTION
8(A), MAY DETERMINE.
================================================================================
SUBJECT TO COMPLETION, DATED JULY 25, 2003
PRELIMINARY PROSPECTUS
LIGAND PHARMACEUTICALS INCORPORATED
5,835,771 SHARES OF COMMON STOCK
The information in this prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. The preliminary prospectus is
not an offer to sell these securities and is not soliciting an offer to buy
these securities in any state where the offer or sale is not permitted.
This prospectus relates to the public offering, which is not being underwritten,
of 5,835,771 shares of our common stock, which is held by some of our current
stockholders. These stockholders acquired the shares from an affiliate of Elan
Corporation, plc in private transactions completed in July 2003.
Our common stock is traded on The Nasdaq Stock Market under the symbol "LGND."
On July 24, 2003, the average of the high and low sales prices for our common
stock was $14.78.
----------------------------------
THE COMMON STOCK OFFERED INVOLVES A HIGH DEGREE OF RISK. SEE "RISK FACTORS"
COMMENCING ON PAGE 6 FOR A DISCUSSION OF SOME IMPORTANT RISKS YOU SHOULD
CONSIDER BEFORE BUYING ANY OF OUR COMMON STOCK.
----------------------------------
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES, OR PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
----------------------------------
The date of this prospectus is July 25, 2003
PROSPECTUS SUMMARY
THE FOLLOWING IS A SUMMARY HIGHLIGHTING SELECTED INFORMATION APPEARING ELSEWHERE
IN THIS PROSPECTUS AND MAY NOT CONTAIN ALL OF THE INFORMATION THAT IS IMPORTANT
TO YOU. THIS PROSPECTUS INCLUDES INFORMATION ABOUT THE SECURITIES WE ARE
OFFERING, AS WELL AS INFORMATION REGARDING OUR BUSINESS AND DETAILED FINANCIAL
DATA. WE ENCOURAGE YOU TO READ THIS PROSPECTUS IN ITS ENTIRETY, INCLUDING THE
DOCUMENTS INCORPORATED BY REFERENCE.
OUR COMPANY
We are a biopharmaceutical company involved in the discovery, development and
commercialization of new drugs that address critical unmet medical needs in the
areas of cancer, pain, men's and women's health or hormone related health
issues, skin diseases, osteoporosis and metabolic, cardiovascular and
inflammatory diseases. Our marketed products and products in development are
designed to be safer, more effective, more convenient (taken orally or topically
administered) and more cost efficient than existing therapies.
We currently market five products and are developing, either exclusively or with
our collaboration partners, 24 selected additional products in development for
multiple therapeutic indications, as summarized in the table below. Our five
marketed products are Avinza(R), ONTAK(R), Targretin(R) capsules, Targretin(R)
gel and Panretin(R) gel. Our efforts are directed toward building a profitable
biopharmaceutical company that generates income from biopharmaceutical products
that we develop and market, and from research, milestone and royalty revenues
from our collaborations with large pharmaceutical partners.
PRODUCT SUMMARY BY THERAPEUTIC AREA (LIGAND AND COLLABORATIVE PARTNERS)
MARKETED PRODUCTS CLINICAL PROGRAMS PRE-CLINICAL PROGRAMS
----------------------------------------------------------------------------------------------------------------------
(5 PRODUCTS) (4 PHASE III/7 PHASE II/6 PHASE I PRODUCTS IN (7 PRODUCTS IN DEVELOPMENT)
DEVELOPMENT)
Cancer Cancer Aging and frailty
Moderate/Severe Pain Hormone replacement therapy Autoimmune diseases
Osteoporosis Dermatology
Dermatology Diabetes
Diabetes Hormone replacement therapy
Inflammation Inflammatory diseases
Thrombocytopenia Sexual dysfunction
Dyslipidemia
OUR MARKETED PRODUCTS
PRODUCT US APPROVED INDICATION EUROPEAN STATUS
----------------------------------------------------------------------------------------------------------------------
Avinza....................... Once-daily treatment of chronic moderate-to-severe
Not applicable pain
ONTAK........................ Cutaneous T-cell lymphoma MAA withdrawn
Targretin capsules........... Cutaneous T-cell lymphoma MA issued
Targretin gel................ Cutaneous T-cell lymphoma MAA withdrawn
Panretin gel................. Kaposi's sarcoma MA issued
AVINZA. Avinza is marketed for the once-daily treatment of chronic
moderate-to-severe pain to patients who require continuous, around-the-clock
opioid therapy. We launched US sales and marketing of Avinza with distribution
in June 2002 and national promotion in July 2002 following receipt of FDA
approval in March 2002. We licensed exclusive rights to Avinza in the United
States and Canada from Elan in 1998. Avinza is an oral once-daily morphine
product and has a more rapid onset and more stable pharmocokinetic profile with
less peak-to-trough fluctuation than other competing sustained release products.
The sustained-release opioid market was estimated at $2.3 billion in the United
States in 2001.
ONTAK. ONTAK is marketed for the treatment of patients with persistent or
recurrent cutaneous T-cell lymphoma, or CTCL. ONTAK was approved by the FDA and
launched in the United States in February 1999 as our first product for the
treatment of patients with CTCL. ONTAK was the first treatment to be approved
for CTCL in nearly 10 years. ONTAK is currently in three Phase II clinical
trials for the treatment of patients with B-cell Non-Hodgkin's lymphoma.
Clinical trials using ONTAK for the treatment of patients with psoriasis,
rheumatoid arthritis and chronic lymphocytic leukemia, or CLL, have also been
conducted, and further trials are being considered. There are
physician-sponsored Phase II trials ongoing in CLL, peripheral T-cell lymphoma
and graft versus host disease. We believe that these indications provide
significantly larger market opportunities than CTCL. A European MAA for CTCL was
filed in December 2001. In April 2003, we withdrew our MAA in Europe for our
first generation product. It was our assessment that the cost of the additional
clinical and technical information requested by the European Agency for the
Evaluation of Medicinal Products for the first generation product would be
better spent on acceleration of the second generation ONTAK development. We
expect to resubmit the MAA in Europe with the second generation product in 2004
or early 2005.
TARGRETIN CAPSULES. Targretin capsules are marketed for the treatment of
patients with CTCL. We launched US sales and marketing of Targretin capsules in
January 2000 following receipt of FDA approval in December 1999. Targretin
capsules offer the convenience of a daily oral dose administered by the patient
at home. We are developing Targretin capsules for a variety of larger market
opportunities, including non-small cell lung cancer and moderate-to-severe
plaque psoriasis. In March 2001, the European Commission granted marketing
authorization for Targretin capsules in Europe for the treatment of patients
with CTCL, and our network of distributors began marketing the drug in Europe in
the fourth quarter of 2001.
TARGRETIN GEL. Targretin gel is marketed for the treatment of patients with
CTCL. We launched US sales and marketing of Targretin gel in September 2000
following receipt of FDA approval in June 2000. Targretin gel offers patients
with refractory, early-stage CTCL a novel, non-invasive, self-administered
treatment topically applied only to the affected areas of the skin. Preliminary
data presented at the American Academy of Dermatology meeting in March 2001
showed that Targretin gel produced an overall response rate of 75% in patients
with untreated, early-stage CTCL. Targretin gel is currently in clinical
development for hand dermatitis, and we released interim Phase I/II data from a
55-patient trial in September 2002.
PANRETIN GEL. Panretin gel is marketed for the treatment of patients with
AIDS-related Kaposi's sarcoma, or KS. Panretin gel was approved by the FDA and
launched in February 1999 as the first FDA-approved patient-applied topical
treatment for AIDS-related Kaposi's sarcoma. Panretin gel represents a
non-invasive option to the traditional management of this disease. Most approved
therapies require the time and expense of periodic visits to a healthcare
facility, where treatment is administered by a doctor or nurse. AIDS-related KS
adversely affects the quality of life of thousands of people in the United
States and Europe. Panretin gel was approved in Europe for the treatment of
patients with KS in October 2000, and was launched through our distributor
network in the fourth quarter of 2001 in Europe.
2
SALES AND MARKETING
As of December 2002, our marketing and selling organization consisted of
approximately 120 people. Since 1998, we had assembled a 35-person sales force
for the United States focused on specialty cancer sales and selling ONTAK,
Targretin capsules, Avinza, Targretin gel and Panretin gel. We have also formed
a separate sales force of approximately 70 representatives to market only Avinza
by targeting pain specialists and general pain centers not currently served by
our specialty cancer representatives. Since a relatively small number of
physicians are responsible for writing a majority of prescriptions in our target
markets, we believe that the size of our sales force is appropriate to reach our
target physicians.
In addition, in February 2003 we entered into an agreement with Organon
Pharmaceuticals USA Inc., a business unit of Akzo Nobel N.V., under which we
co-promote Avinza with Organon's primary care, hospital (anesthesiology) and
specialty (pain centers) sales forces, which together consist of more than 700
sales representatives.
COLLABORATIVE RESEARCH AND DEVELOPMENT PROGRAMS
We are currently involved in the research phase of research and development
collaborations with Eli Lilly and TAP Pharmaceuticals. Collaborations in the
development phase are being pursued by Abbott Laboratories, Allergan,
GlaxoSmithKline, Organon (AKZO-Nobel), Pfizer and Wyeth (formerly American Home
Products). Currently, our corporate partners have 10 Ligand products in human
development, four products moving toward regulatory filings for human clinical
trials and numerous compounds in research and pre-clinical stages. These
products are being studied for the treatment of health problems in large markets
such as osteoporosis, diabetes, contraception and cardiovascular disease. Three
of these partner products are being tested in three separate pivotal Phase III
clinical trial programs: lasofoxifene, which is being developed by Pfizer for
osteoporosis; and bazedoxifene (formerly TSE-424), which is being developed by
Wyeth both as monotherapy for osteoporosis and in combination with Wyeth's
Premarin as hormone replacement therapy, or HRT.
PROPRIETARY TECHNOLOGY PLATFORM
Internal and collaborative research and development programs are built around
our proprietary science technology, which is based on our leadership position in
gene transcription technology, a technology for regulating how genes control
cellular activity. Our proprietary technologies involve two natural mechanisms
that regulate gene activity: hormone-activated intracellular receptors, or IRs,
a type of sensor or switch inside cells that turns genes on and off and alters
the production of proteins in response to hormones, and Signal Transducers and
Activators of Transcription, or STATs, another type of protein production
switch. Targretin capsules, Targretin gel, Panretin gel and all but one of our
corporate partner products currently on human development track were discovered
using our IR technology.
PRODUCT PIPELINE SUMMARY
We are developing several proprietary products for which we have worldwide
rights for a variety of cancers, skin diseases and other indications, as
summarized in the table below. Many of the indications being pursued may present
larger market opportunities for our currently marketed products. Our clinical
development programs are primarily based on products discovered through our IR
technology, with the exception of ONTAK, which was developed using Seragen's
fusion protein technology, and Avinza, which was developed by Elan. Five of the
products in our proprietary product development programs are retinoids,
discovered and developed using our proprietary IR technology. Our research is
based on both our IR and STAT technologies. In addition to our proprietary
product pipeline, our collaborative partners have multiple products in human
development, as well as numerous compounds in research and pre-clinical stages.
3
PRODUCT PIPELINE SUMMARY (CONTINUED)
PRODUCT CLINICAL INDICATION DEVELOPMENT COMMERCIALIZATION RIGHTS
STATUS
----------------------------------------------------------------------------------------------------------------------
OUR MARKETED PRODUCTS AND DEVELOPMENT PROGRAMS
Avinza..................... Chronic pain (moderate-to-severe) Marketed United States and Canada
ONTAK...................... Cutaneous T-cell lymphoma Marketed Worldwide
Peripheral T-cell lymphoma Phase II
Chronic lymphocytic leukemia Phase II
B-cell Non-Hodgkin's lymphoma Phase II
Psoriasis (severe) Phase II
Targretin capsules......... Cutaneous T-cell lymphoma Marketed Worldwide
Non-small cell lung cancer Phase III
(combination and monotherapy)
Psoriasis (moderate to severe) Phase II
Advanced breast cancer Phase II
Renal cell cancer Phase II
Targretin gel.............. Cutaneous T-cell lymphoma Marketed Worldwide
Hand dermatitis Phase II
Psoriasis Phase II
Panretin gel............... Kaposi's sarcoma Marketed Worldwide
Panretin capsules.......... Kaposi's sarcoma, bronchial metaplasia Phase II Worldwide
LGD 1550................... Advanced cancers Phase II Worldwide
Acne, psoriasis Pre-clinical
LGD 1331................... Acne, prostate cancer, androgenetic Pre-clinical Worldwide
alopecia, hirsutism
Glucocorticoid agonist..... Inflammation, cancer Pre-clinical Worldwide
Mineralocorticoid receptor
modulators.............. Congestive heart failure, hypertension Research Worldwide
OUR COLLABORATIVE RESEARCH AND DEVELOPMENT PROGRAMS
Lasofoxifene............... Osteoporosis and breast cancer prevention Phase III Pfizer
Bazedoxifene (TSE424)...... Osteoporosis Phase III Wyeth
Bazedoxifene Premarin...... Hormone replacement therapy Phase III Wyeth
ERA 923.................... Breast cancer Phase II Wyeth
NSP 989.................... Contraception, hormone replacement therapy Phase I Wyeth
NSP 989 combo.............. Contraception Phase I Wyeth
GW 516 (501516)............ Dyslipidemia Phase I GlaxoSmithKline
LY 929..................... Type II diabetes, dyslipidemia Phase I Lilly
LY 818..................... Type II diabetes Phase II Lilly
SB-497115.................. Thrombocytopenia Phase I GlaxoSmithKline
LY 674..................... Dyslipidemia Phase I Lilly
LGD 2226/back-ups.......... Sexual dysfunction--hypogonadism IND Track TAP
LY YYY..................... Type II diabetes, dyslipidemia IND Track Lilly
LY WWW..................... Dyslipidemia IND Track Lilly
------------------------------------------------------------------------------------------------------------------------
4
Our principal executive offices are located at 10275 Science Center Drive, San
Diego, California 92121, and our telephone number is (858) 550-7500. Our website
is located at WWW.LIGAND.COM. The information on our website is not a part of
this prospectus.
Our trademarks, trade names and service marks referenced in this document
include Ligand(R), Avinza(R), ONTAK(R), Panretin(R) and Targretin(R). Each other
trademark, trade name or service mark appearing in this document belongs to its
holder.
Reference to Ligand Pharmaceuticals Incorporated, "Ligand," the "Company," "we"
or "our" include Ligand's wholly owned subsidiaries, Glycomed Incorporated,
Ligand Pharmaceuticals (Canada) Incorporated, Ligand Pharmaceuticals
International, Inc., and Seragen, Inc.
RECENT DEVELOPMENTS
EXTENSION OF R&D COLLABORATION WITH ELI LILLY AND COMPANY
On May 8, 2003, we announced the second extension, until November 2004, of our
research collaboration with Eli Lilly and Company focused on discovering novel
drugs for type II diabetes and cardiovascular disorders. The Lilly-Ligand
collaboration, which began in 1997, already has advanced three peroxisome
proliferation activated receptor, or PPAR, modulators into clinical studies.
PPARs are a subfamily of intracellular receptors that regulate glucose and lipid
homeostasis. They play a key role in enhancing cellular responses to insulin,
and in fat tissue stores and metabolism.
ORGANIZATIONAL CHANGES
On May 15, 2003, we announced the following organizational changes:
>> Andres Negro-Vilar, M.D., P.h.D. was promoted to Executive Vice President
for Research and Development and Chief Scientific Officer. Dr. Negro-Vilar
was previously our Senior Vice President for Research and Development;
>> Tod Mertes was promoted to Vice President and Controller. Mr. Mertes was
previously our Director of Finance;
>> Tom Silberg left to pursue other opportunities. Mr. Silberg was formerly
our Executive Vice President and Chief Operating Officer; and
>> Gian Aliprandi was promoted to Senior Vice President for Technical, Supply
and International Operations. Mr. Aliprandi was previously our Vice
President, Senior Corporate Controller and Treasurer.
MILESTONE PAYMENT AS GLAXOSMITHKLINE ADVANCES DEVELOPMENT OF 501516
On June 4, 2003, we announced that we had earned a $1.0 million milestone
payment from GlaxoSmithKline as a result of GlaxoSmithKline's decision to
continue Phase I development of 501516, a novel PPAR modulator for the treatment
of dyslipidemias. Under the recently amended terms of our research and
development agreement with GlaxoSmithKline, GlaxoSmithKline is responsible for
the development and registration of 501516, and may pay us milestone payments of
up to $14 million as the product moves through the development process.
GlaxoSmithKline has exclusive worldwide marketing rights to 501516, and will pay
us up to double-digit royalties on potential product sales. If GlaxoSmithKline
decides not to proceed with development of 501516, we will retain the right to
develop and commercialize the product.
5
RISK FACTORS
IN ADDITION TO THE OTHER INFORMATION IN THIS PROSPECTUS, YOU SHOULD
CAREFULLY CONSIDER THE FOLLOWING RISKS AND UNCERTAINTIES BEFORE PURCHASING OUR
SECURITIES. EACH OF THESE RISKS AND UNCERTAINTIES COULD ADVERSELY AFFECT OUR
BUSINESS, OPERATING RESULTS AND FINANCIAL CONDITION, AS WELL AS THE VALUE OF AN
INVESTMENT IN OUR SECURITIES.
RISKS RELATED TO US AND OUR BUSINESS
OUR PRODUCT DEVELOPMENT AND COMMERCIALIZATION INVOLVES A NUMBER OF
UNCERTAINTIES, AND WE MAY NEVER GENERATE SUFFICIENT REVENUES FROM THE SALE OF
PRODUCTS TO BECOME PROFITABLE.
We were founded in 1987. We have incurred significant losses since our
inception. At March 31, 2003, our accumulated deficit was approximately $639
million. To date, we have received the majority of our revenues from our
collaborative arrangements and only began receiving revenues from the sale of
pharmaceutical products in 1999. To become profitable, we must successfully
develop, clinically test, market and sell our products. Even if we achieve
profitability, we cannot predict the level of that profitability or whether we
will be able to sustain profitability. We expect that our operating results will
fluctuate from period to period as a result of differences in when we incur
expenses and receive revenues from product sales, collaborative arrangements and
other sources. Some of these fluctuations may be significant.
Most of our products in development will require extensive additional
development, including preclinical testing and human studies, as well as
regulatory approvals, before we can market them. We cannot predict if or when
any of the products we are developing or those being co-developed with our
partners will be approved for marketing. There are many reasons that we or our
collaborative partners may fail in our efforts to develop our other potential
products, including the possibility that:
>> preclinical testing or human studies may show that our potential products
are ineffective or cause harmful side effects;
>> the products may fail to receive necessary regulatory approvals from the
FDA or foreign authorities in a timely manner, or at all;
>> the products, if approved, may not be produced in commercial quantities or
at reasonable costs;
>> the products, once approved, may not achieve commercial acceptance;
>> regulatory or governmental authorities may apply restrictions to our
products, which could adversely affect their commercial success; or
>> the proprietary rights of other parties may prevent us or our partners from
marketing the products.
WE ARE BUILDING MARKETING AND SALES CAPABILITIES IN THE UNITED STATES AND EUROPE
WHICH IS AN EXPENSIVE AND TIME-CONSUMING PROCESS AND MAY INCREASE OUR OPERATING
LOSSES.
Developing the sales force to market and sell products is a difficult, expensive
and time-consuming process. We have developed a US sales force of about 90
people. We also rely on third-party distributors to distribute our products. The
distributors are responsible for providing many marketing support services,
including customer service, order entry, shipping and billing and customer
reimbursement assistance. In Europe, we will rely initially on other companies
to distribute and market our products. We have entered into agreements for the
marketing and distribution of our products in territories such as the United
Kingdom, Germany, France, Spain, Portugal, Greece, Italy and Central and South
America and have established a subsidiary, Ligand Pharmaceuticals International,
Inc., with a branch in London, England, to coordinate our European marketing and
operations. Our reliance on these third parties means our results may suffer if
any of them are unsuccessful or fail to perform as expected. We may not be able
to continue to expand our sales and marketing capabilities sufficiently to
successfully commercialize our products in the territories where they receive
marketing approval. With respect to our co-promotion or licensing arrangements,
for example our co-promotion agreement for Avinza, any revenues we receive will
depend substantially on the marketing and sales efforts of others, which may or
may not be successful.
6
OUR SMALL NUMBER OF PRODUCTS MEANS OUR RESULTS ARE VULNERABLE TO SETBACKS WITH
RESPECT TO ANY ONE PRODUCT.
We currently have only five products approved for marketing and a handful of
other products/indications that have made significant progress through
development. Because these numbers are small, especially the number of marketed
products, any significant setback with respect to any one of them could
significantly impair our operating results and/or reduce the market prices for
our securities. Setbacks could include problems with shipping, distribution,
manufacturing, product safety, marketing, government licenses and approvals,
intellectual property rights and physician or patient acceptance of the product.
SALES OF OUR SPECIALTY PHARMACEUTICAL PRODUCTS MAY SIGNIFICANTLY FLUCTUATE EACH
PERIOD BASED ON THE NATURE OF OUR PRODUCTS, OUR PROMOTIONAL ACTIVITIES AND
WHOLESALER PURCHASING AND STOCKING PATTERNS.
Excluding Avinza, our products are small-volume specialty pharmaceutical
products that address the needs of cancer patients in relatively small niche
markets with substantial geographical fluctuations in demand. To ensure patient
access to our drugs, we maintain broad distribution capabilities with
inventories held at approximately 125 locations throughout the United States.
Furthermore, the purchasing and stocking patterns of our wholesaler customers
are influenced by a number of factors that vary with each product, including but
not limited to overall level of demand, periodic promotions, required minimum
shipping quantities and wholesaler competitive initiatives. As a result, the
level of product in the distribution channel may average from two to six months'
worth of projected inventory usage. If any or all of our major distributors
decide to substantially reduce the inventory they carry in a given period, our
sales for that period could be substantially lower than historical levels.
OUR DRUG DEVELOPMENT PROGRAMS WILL REQUIRE SUBSTANTIAL ADDITIONAL FUTURE FUNDING
WHICH COULD HURT OUR OPERATIONAL AND FINANCIAL CONDITION.
Our drug development programs require substantial additional capital to
successfully complete them, arising from costs to:
>> conduct research, preclinical testing and human studies;
>> establish pilot scale and commercial scale manufacturing processes and
facilities; and
>> establish and develop quality control, regulatory, marketing, sales and
administrative capabilities to support these programs.
Our future operating and capital needs will depend on many factors, including:
>> the pace of scientific progress in our research and development programs
and the magnitude of these programs;
>> the scope and results of preclinical testing and human studies;
>> the time and costs involved in obtaining regulatory approvals;
>> the time and costs involved in preparing, filing, prosecuting, maintaining
and enforcing patent claims, competing technological and market
developments;
>> our ability to establish additional collaborations;
>> changes in our existing collaborations;
>> the cost of manufacturing scale-up; and
>> the effectiveness of our commercialization activities.
We currently estimate our research and development expenditures over the next 3
years to range between $200 million and $275 million. However, we base our
outlook regarding the need for funds on many uncertain variables. Such
uncertainties include regulatory approvals, the timing of events outside our
direct control such as product launches by partners and the success of such
product launches, negotiations with potential strategic partners and other
factors. Any of these uncertain events can significantly change our cash
requirements as they determine such one-time events as the receipt of major
milestones and other payments.
7
While we expect to fund our research and development activities from cash
generated from internal operations to the extent possible, if we are unable to
do so we may need to complete additional equity or debt financings or seek other
external means of financing. If additional funds are required to support our
operations and we are unable to obtain them on terms favorable to us, we may be
required to cease or reduce further development or commercialization of our
products, to sell some or all of our technology or assets or to merge with
another entity.
SOME OF OUR KEY TECHNOLOGIES HAVE NOT BEEN USED TO PRODUCE MARKETED PRODUCTS AND
MAY NOT BE CAPABLE OF PRODUCING SUCH PRODUCTS.
To date, we have dedicated most of our resources to the research and development
of potential drugs based upon our expertise in our IR and STAT technologies.
Even though there are marketed drugs that act through IRs, some aspects of our
IR technologies have not been used to produce marketed products. In addition, we
are not aware of any drugs that have been developed and successfully
commercialized that interact directly with STATs. Much remains to be learned
about the location and function of IRs and STATs. If we are unable to apply our
IR and STAT technologies to the development of our potential products, we will
not be successful in developing new products.
WE MAY REQUIRE ADDITIONAL MONEY TO RUN OUR BUSINESS AND MAY BE REQUIRED TO RAISE
THIS MONEY ON TERMS WHICH ARE NOT FAVORABLE OR WHICH REDUCE OUR STOCK PRICE.
We have incurred losses since our inception and may not generate positive cash
flow to fund our operations for one or more years. As a result, we may need to
complete additional equity or debt financings to fund our operations. Our
inability to obtain additional financing could adversely affect our business.
Financings may not be available at all or on favorable terms. In addition, these
financings, if completed, still may not meet our capital needs and could result
in substantial dilution to our stockholders. For instance, in February and March
2002 we issued to Elan 6.3 million shares upon the conversion of zero coupon
convertible senior notes held by Elan, and in April 2002 we issued 4.3 million
shares of our common stock, in a private placement. These transactions have
resulted in the issuance of significant numbers of new shares. In addition, in
November 2002 we issued in a private placement $155,250,000 in aggregate
principal amount of our 6% convertible subordinated notes due 2007, which could
be converted into 25,149,025 shares of our common stock.
If adequate funds are not available, we may be required to delay, reduce the
scope of or eliminate one or more of our research or drug development programs,
or our marketing and sales initiatives. Alternatively, we may be forced to
attempt to continue development by entering into arrangements with collaborative
partners or others that require us to relinquish some or all of our rights to
technologies or drug candidates that we would not otherwise relinquish.
OUR PRODUCTS FACE SIGNIFICANT REGULATORY HURDLES PRIOR TO MARKETING WHICH COULD
DELAY OR PREVENT SALES. EVEN AFTER APPROVAL, GOVERNMENT REGULATION OF OUR
BUSINESS IS EXTENSIVE.
Before we obtain the approvals necessary to sell any of our potential products,
we must show through preclinical studies and human testing that each product is
safe and effective. We and our partners have a number of products moving toward
or currently in clinical trials, the most significant of which are our Phase III
trials for Targretin capsules in non-small cell lung cancer and three Phase III
trials by our partners involving bazedoxifene and lasofoxifene. Failure to show
any product's safety and effectiveness would delay or prevent regulatory
approval of the product and could adversely affect our business. The clinical
trials process is complex and uncertain. The results of preclinical studies and
initial clinical trials may not necessarily predict the results from later
large-scale clinical trials. In addition, clinical trials may not demonstrate a
product's safety and effectiveness to the satisfaction of the regulatory
authorities. A number of companies have suffered significant setbacks in
advanced clinical trials or in seeking regulatory approvals, despite promising
results in earlier trials. The FDA may also require additional clinical trials
after regulatory approvals are received, which could be expensive and
time-consuming, and failure to successfully conduct those trials could
jeopardize continued commercialization.
8
The rate at which we complete our clinical trials depends on many factors,
including our ability to obtain adequate supplies of the products to be tested
and patient enrollment. Patient enrollment is a function of many factors,
including the size of the patient population, the proximity of patients to
clinical sites and the eligibility criteria for the trial. For example, each of
our Phase III Targretin clinical trials will involve approximately 600 patients
and may require significant time and investment to complete enrollments. Delays
in patient enrollment may result in increased costs and longer development
times. In addition, our collaborative partners have rights to control product
development and clinical programs for products developed under the
collaborations. As a result, these collaborators may conduct these programs more
slowly or in a different manner than we had expected. Even if clinical trials
are completed, we or our collaborative partners still may not apply for FDA
approval in a timely manner or the FDA still may not grant approval.
In addition, the manufacturing and marketing of approved products is subject to
extensive government regulation, including by the FDA, DEA and state and other
territorial authorities. The FDA administers processes to assure that marketed
products are safe, effective, consistently of uniform, high quality and marketed
only for approved indications. For example, while our products are prescribed
legally by some physicians for unapproved uses, we may not market our products
for such uses. Failure to comply with applicable regulatory requirements can
result in sanctions up to the suspension of regulatory approval as well as civil
and criminal sanctions.
WE FACE SUBSTANTIAL COMPETITION WHICH MAY LIMIT OUR REVENUES.
Some of the drugs that we are developing and marketing will compete with
existing treatments. In addition, several companies are developing new drugs
that target the same diseases that we are targeting and are taking IR-related
and STAT-related approaches to drug development. The principal products
competing with our products targeted at the cutaneous t-cell lymphoma market are
Supergen/Abbott's Nipent and interferon, which is marketed by a number of
companies, including Schering-Plough's Intron A. Products that compete with
Avinza include Purdue Pharma L.P.'s OxyContin and MS Contin, Janssen
Pharmaceutica Products, L.P.'s Duragesic, Elan's Oramorph SR and Faulding's
Kadian. Many of our existing or potential competitors, particularly large drug
companies, have greater financial, technical and human resources than us and may
be better equipped to develop, manufacture and market products. Many of these
companies also have extensive experience in preclinical testing and human
clinical trials, obtaining FDA and other regulatory approvals and manufacturing
and marketing pharmaceutical products. In addition, academic institutions,
governmental agencies and other public and private research organizations are
developing products that may compete with the products we are developing. These
institutions are becoming more aware of the commercial value of their findings
and are seeking patent protection and licensing arrangements to collect payments
for the use of their technologies. These institutions also may market
competitive products on their own or through joint ventures and will compete
with us in recruiting highly qualified scientific personnel.
THIRD-PARTY REIMBURSEMENT AND HEALTH CARE REFORM POLICIES MAY REDUCE OUR FUTURE
SALES.
Sales of prescription drugs depend significantly on the availability of
reimbursement to the consumer from third party payers, such as government and
private insurance plans. These third party payers frequently require drug
companies to provide predetermined discounts from list prices, and they are
increasingly challenging the prices charged for medical products and services.
Our current and potential products may not be considered cost-effective, and
reimbursement to the consumer may not be available or sufficient to allow us to
sell our products on a competitive basis. For example, we have current and
recurring discussions with insurers regarding reimbursement rates for our drugs,
including Avinza which was recently approved for marketing. We may not be able
to negotiate favorable reimbursement rates for our products or may have to pay
significant discounts to obtain favorable rates. Only one of our products,
ONTAK, is currently eligible to be reimbursed by Medicare. Proposed changes by
Medicare to the hospital outpatient payment reimbursement system may adversely
affect reimbursement rates for ONTAK.
9
In addition, the efforts of governments and third-party payers to contain or
reduce the cost of health care will continue to affect the business and
financial condition of drug companies such as us. A number of legislative and
regulatory proposals to change the health care system have been discussed in
recent years, including price caps and controls for pharmaceuticals. These
proposals could reduce and/or cap the prices for our products or reduce
government reimbursement rates for products such as ONTAK. In addition, an
increasing emphasis on managed care in the United States has and will continue
to increase pressure on drug pricing. We cannot predict whether legislative or
regulatory proposals will be adopted or what effect those proposals or managed
care efforts may have on our business. The announcement and/or adoption of such
proposals or efforts could adversely affect our profit margins and business.
WE RELY HEAVILY ON COLLABORATIVE RELATIONSHIPS AND TERMINATION OF ANY OF THESE
PROGRAMS COULD REDUCE THE FINANCIAL RESOURCES AVAILABLE TO US, INCLUDING
RESEARCH FUNDING AND MILESTONE PAYMENTS.
Our strategy for developing and commercializing many of our potential products,
including products aimed at larger markets, includes entering into
collaborations with corporate partners, licensors, licensees and others. These
collaborations provide us with funding and research and development resources
for potential products for the treatment or control of metabolic diseases,
hematopoiesis, women's health disorders, inflammation, cardiovascular disease,
cancer and skin disease, and osteoporosis. These agreements also give our
collaborative partners significant discretion when deciding whether or not to
pursue any development program. Our collaborations may not continue or be
successful.
In addition, our collaborators may develop drugs, either alone or with others,
that compete with the types of drugs they currently are developing with us. This
would result in less support and increased competition for our programs. If
products are approved for marketing under our collaborative programs, any
revenues we receive will depend on the manufacturing, marketing and sales
efforts of our collaborators, who generally retain commercialization rights
under the collaborative agreements. Our current collaborators also generally
have the right to terminate their collaborations under specified circumstances.
If any of our collaborative partners breach or terminate their agreements with
us or otherwise fail to conduct their collaborative activities successfully, our
product development under these agreements will be delayed or terminated.
We may have disputes in the future with our collaborators, including disputes
concerning which of us owns the rights to any technology developed. For
instance, we were involved in litigation with Pfizer, which we settled in April
1996, concerning our right to milestones and royalties based on the development
and commercialization of droloxifene. These and other possible disagreements
between us and our collaborators could delay our ability and the ability of our
collaborators to achieve milestones or our receipt of other payments. In
addition, any disagreements could delay, interrupt or terminate the
collaborative research, development and commercialization of certain potential
products, or could result in litigation or arbitration. The occurrence of any of
these problems could be time-consuming and expensive and could adversely affect
our business. Challenges to or failure to secure patents and other proprietary
rights may significantly hurt our business. Our success will depend on our
ability and the ability of our licensors to obtain and maintain patents and
proprietary rights for our potential products and to avoid infringing the
proprietary rights of others, both in the United States and in foreign
countries. Patents may not be issued from any of these applications currently on
file, or, if issued, may not provide sufficient protection. In addition,
disputes with licensors under our license agreements may arise which could
result in additional financial liability or loss of important technology and
potential products and related revenue, if any.
Our patent position, like that of many pharmaceutical companies, is uncertain
and involves complex legal and technical questions for which important legal
principles are unresolved. We may not develop or obtain rights to products or
processes that are patentable. Even if we do obtain patents, they may not
adequately protect the technology we own or have licensed. In addition, others
may challenge, seek to invalidate, infringe or circumvent any patents we own or
license, and rights we receive under those patents may not provide competitive
advantages to us. Further, the manufacture, use or sale of our products may
infringe the patent rights of others.
10
Several drug companies and research and academic institutions have developed
technologies, filed patent applications or received patents for technologies
that may be related to our business. Others have filed patent applications and
received patents that conflict with patents or patent applications we have
licensed for our use, either by claiming the same methods or compounds or by
claiming methods or compounds that could dominate those licensed to us. In
addition, we may not be aware of all patents or patent applications that may
impact our ability to make, use or sell any of our potential products. For
example, US patent applications may be kept confidential while pending in the
Patent and Trademark Office and patent applications filed in foreign countries
are often first published six months or more after filing. Any conflicts
resulting from the patent rights of others could significantly reduce the
coverage of our patents and limit our ability to obtain meaningful patent
protection. While we routinely receive communications or have conversations with
the owners of other patents, none of these third parties have directly
threatened an action or claim against us. If other companies obtain patents with
conflicting claims, we may be required to obtain licenses to those patents or to
develop or obtain alternative technology. We may not be able to obtain any such
licenses on acceptable terms, or at all. Any failure to obtain such licenses
could delay or prevent us from pursuing the development or commercialization of
our potential products.
We have had and will continue to have discussions with our current and potential
collaborators regarding the scope and validity of our patents and other
proprietary rights. If a collaborator or other party successfully establishes
that our patent rights are invalid, we may not be able to continue our existing
collaborations beyond their expiration. Any determination that our patent rights
are invalid also could encourage our collaborators to terminate their agreements
where contractually permitted. Such a determination could also adversely affect
our ability to enter into new collaborations.
We may also need to initiate litigation, which could be time-consuming and
expensive, to enforce our proprietary rights or to determine the scope and
validity of others' rights. If litigation results, a court may find our patents
or those of our licensors invalid or may find that we have infringed on a
competitor's rights. If any of our competitors have filed patent applications in
the United States which claim technology we also have invented, the Patent and
Trademark Office may require us to participate in expensive interference
proceedings to determine who has the right to a patent for the technology.
We have learned that Hoffmann-La Roche Inc. has received a US patent and has
made patent filings in foreign countries that relate to our Panretin capsules
and gel products. We filed a patent application with an earlier filing date than
Hoffmann-La Roche's patent, which we believe is broader than, but overlaps in
part with, Hoffmann-La Roche's patent. We believe we were the first to invent
the relevant technology and therefore are entitled to a patent on the
application we filed. The Patent and Trademark Office has initiated a proceeding
to determine whether we or Hoffmann-La Roche are entitled to a patent. We may
not receive a favorable outcome in the proceeding. In addition, the proceeding
may delay the Patent and Trademark Office's decision regarding our earlier
application. If we do not prevail, the Hoffmann-La Roche patent might block our
use of Panretin capsules and gel in specified cancers.
We have also learned that Novartis AG has filed an opposition to our European
patent that covers the principal active ingredient of our ONTAK drug. We are
currently investigating the scope and merits of this opposition. If the
opposition is successful, we could lose our ONTAK patent protection in Europe
which could substantially reduce our future ONTAK sales in that region. We could
also incur substantial costs in asserting our rights in this opposition
proceeding, as well as in other interference proceedings in the United States.
We also rely on unpatented trade secrets and know-how to protect and maintain
our competitive position. We require our employees, consultants, collaborators
and others to sign confidentiality agreements when they begin their relationship
with us. These agreements may be breached, and we may not have adequate remedies
for any breach. In addition, our competitors may independently discover our
trade secrets.
11
RELIANCE ON THIRD-PARTY MANUFACTURERS TO SUPPLY OUR PRODUCTS RISKS SUPPLY
INTERRUPTION OR CONTAMINATION AND DIFFICULTY CONTROLLING COSTS.
We currently have no manufacturing facilities, and we rely on others for
clinical or commercial production of our marketed and potential products. In
addition, certain raw materials necessary for the commercial manufacturing of
our products are custom and must be obtained from a specific sole source. Elan
manufactures Avinza for us, Cambrex manufactures ONTAK for us and RP Scherer and
Raylo manufacture Targretin capsules for us.
To be successful, we will need to ensure continuity of the manufacture of our
products, either directly or through others, in commercial quantities, in
compliance with regulatory requirements and at acceptable cost. Any extended and
unplanned manufacturing shutdowns could be expensive and could result in
inventory and product shortages. While we believe that we would be able to
develop our own facilities or contract with others for manufacturing services
with respect to all of our products, if we are unable to do so our revenues
could be adversely affected. In addition, if we are unable to supply products in
development, our ability to conduct preclinical testing and human clinical
trials will be adversely affected. This in turn could also delay our submission
of products for regulatory approval and our initiation of new development
programs. In addition, although other companies have manufactured drugs acting
through IRs and STATs on a commercial scale, we may not be able to do so at
costs or in quantities to make marketable products.
The manufacturing process also may be susceptible to contamination, which could
cause the affected manufacturing facility to close until the contamination is
identified and fixed. In addition, problems with equipment failure or operator
error also could cause delays in filling our customers' orders.
OUR BUSINESS EXPOSES US TO PRODUCT LIABILITY RISKS OR OUR PRODUCTS MAY NEED TO
BE RECALLED, AND WE MAY NOT HAVE SUFFICIENT INSURANCE TO COVER ANY CLAIMS.
Our business exposes us to potential product liability risks. Our products also
may need to be recalled to address regulatory issues. A successful product
liability claim or series of claims brought against us could result in payment
of significant amounts of money and divert management's attention from running
the business. Some of the compounds we are investigating may be harmful to
humans. For example, retinoids as a class are known to contain compounds which
can cause birth defects. We may not be able to maintain our insurance on
acceptable terms, or our insurance may not provide adequate protection in the
case of a product liability claim. To the extent that product liability
insurance, if available, does not cover potential claims, we will be required to
self-insure the risks associated with such claims. We believe that we carry
reasonably adequate insurance for product liability claims.
WE USE HAZARDOUS MATERIALS WHICH REQUIRES US TO INCUR SUBSTANTIAL COSTS TO
COMPLY WITH ENVIRONMENTAL REGULATIONS.
In connection with our research and development activities, we handle hazardous
materials, chemicals and various radioactive compounds. To properly dispose of
these hazardous materials in compliance with environmental regulations, we are
required to contract with third parties at substantial cost to us. Our annual
cost of compliance with these regulations is approximately $600,000. We cannot
completely eliminate the risk of accidental contamination or injury from the
handling and disposing of hazardous materials, whether by us or by our
third-party contractors. In the event of any accident, we could be held liable
for any damages that result, which could be significant. We believe that we
carry reasonably adequate insurance for toxic tort claims.
OUR STOCK PRICE MAY BE ADVERSELY AFFECTED BY VOLATILITY IN THE MARKETS.
The market prices and trading volumes for our securities, and the securities of
emerging companies like us, have historically been highly volatile and have
experienced significant fluctuations unrelated to operating performance. For
example, in 2002, the intraday sale price of our common stock on the Nasdaq
National Market was as high as $20.50 and as low as $4.64. Future announcements
concerning us or our competitors as well as other companies in our industry and
other public companies may impact the market price of our common stock. These
announcements might include:
12
>> the results of research or development testing of ours or our competitors'
products;
>> technological innovations related to diseases we are studying;
>> new commercial products introduced by our competitors;
>> government regulation of our industry;
>> receipt of regulatory approvals by our competitors;
>> our failure to receive regulatory approvals for products under development;
>> developments concerning proprietary rights;
>> litigation or public concern about the safety of our products; or
>> intent to sell or actual sale of our stock held by our corporate partners.
AS A NEW INVESTOR, YOU MAY EXPERIENCE IMMEDIATE AND SUBSTANTIAL DILUTION.
The offering price of our common stock may be substantially higher than the net
tangible book value per share of our common stock. If you purchase common stock
in this offering from a selling stockholder for the per-share purchase price of
$14.78, which is the average of the high and low sales prices per share of the
common stock on July 24, 2003 as reported on The Nasdaq Stock Market, you will
incur immediate dilution in tangible net book value of approximately $16.34 per
share, based on our tangible net book value of $(1.56) at March 31, 2003.
FUTURE SALES OF OUR SECURITIES MAY DEPRESS THE PRICE OF OUR SECURITIES.
Sales of substantial amounts of our securities in the public market could
seriously harm prevailing market prices for our securities. These sales might
make it difficult or impossible for us to sell additional securities when we
need to raise capital.
YOU MAY NOT RECEIVE A RETURN ON YOUR SECURITIES OTHER THAN THROUGH THE SALE OF
YOUR SECURITIES.
We have not paid any cash dividends on our common stock to date. We intend to
retain any earnings to support the expansion of our business, and we do not
anticipate paying cash dividends on any of our securities in the foreseeable
future.
OUR SHAREHOLDER RIGHTS PLAN AND CHARTER DOCUMENTS MAY HINDER OR PREVENT CHANGE
OF CONTROL TRANSACTIONS.
Our shareholder rights plan and provisions contained in our certificate of
incorporation and bylaws may discourage transactions involving an actual or
potential change in our ownership. In addition, our board of directors may issue
shares of preferred stock without any further action by you. Such issuances may
have the effect of delaying or preventing a change in our ownership. If changes
in our ownership are discouraged, delayed or prevented, it would be more
difficult for our current board of directors to be removed and replaced, even if
you or our other stockholders believe that such actions are in the best
interests of us and our stockholders.
13
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus may contain forward-looking statements that involve
substantial risks and uncertainties regarding future events or our future
performance within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You
can identify these statements by forward-looking words such as "may," "will,"
"expect," "intent," "anticipate," "believe," "estimate" and "continue" or
similar words. You should read statements that contain these words carefully
because they discuss our future expectations, contain projections of our future
results of operations or of our financial condition or state other
"forward-looking" information. We believe that it is important to communicate
our future expectations to our investors. However, there may be events in the
future that we are not able to accurately predict or control. The factors listed
in the section captioned "Risk Factors," as well as any cautionary language
included in this prospectus or incorporated by reference, provide examples of
risks, uncertainties and events that may cause our actual results to differ
materially from the expectations we describe in our forward-looking statements.
Before you invest in our common stock, you should be aware that the occurrence
of the events described in the "Risk Factors" section and elsewhere in this
prospectus could have a material adverse effect on our business, operating
results and financial condition. All subsequent written and oral forward-looking
statements attributable to us or persons acting on our behalf are expressly
qualified in their entirety by these statements.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements and other
information with the SEC. You may read and copy any document we file at the
SEC's public reference rooms at 450 Fifth Street, N.W., Washington, D.C. 20549.
Please call the SEC at 1-800-SEC-0330 for further information on the public
reference rooms. Our SEC filings are also available to the public on the SEC's
website at http://www.sec.gov.
14
INFORMATION INCORPORATED BY REFERENCE
The SEC allows us to incorporate by reference the information we file with
them, which means that we can disclose important information to you by referring
you to those documents. The information incorporated by reference is considered
to be part of this prospectus, and later information filed with the SEC will
update and supersede this information. We incorporate by reference the documents
listed below and any future filings we make with the SEC under Section 13(a),
13(c), 14, or 15(d) of the Securities Exchange Act of 1934 from the date of the
initial registration statement until the completion of the offering of the
securities covered by this prospectus:
o Our annual report on Form 10-K for the fiscal year ended December 31, 2002,
o Our quarterly report on Form 10-Q for the quarterly period ended March 31,
2003,
o Our current reports on Form 8-K filed February 25, 2003, April 2, 2003,
April 24, 2003 and May 15, 2003,
o The description of our common stock, contained in our registration
statement on Form 8-A filed on November 21, 1994, including any amendments
or reports filed for the purpose of updating such descriptions, and
o The description of our preferred stock purchase rights, contained in our
registration statement on Form 8-A filed on September 30, 1996, including
any amendments or reports filed for the purpose of updating such
descriptions.
The reports and other documents that we file after the date of this
prospectus will update and supersede the information in this prospectus.
You may request a copy of these filings, at no cost, by writing or
telephoning us at:
Ligand Pharmaceuticals Incorporated
Attn: Investor Relations
10275 Science Center Road
San Diego, California 92121-1117
(858) 550-7500
YOU SHOULD RELY ONLY ON THE INFORMATION PROVIDED OR INCORPORATED BY
REFERENCE IN THIS PROSPECTUS OR ANY RELATED PROSPECTUS SUMMARY. WE HAVE NOT
AUTHORIZED ANYONE TO PROVIDE YOU WITH DIFFERENT INFORMATION. YOU SHOULD NOT
ASSUME THAT THE INFORMATION IN THIS PROSPECTUS OR ANY RELATED PROSPECTUS SUMMARY
IS ACCURATE AS OF ANY DATE OTHER THAN THE DATE ON THE FRONT OF THE DOCUMENT.
15
DILUTION
The net tangible book value of Ligand at March 31, 2003 was $(107,839,000),
or approximately $(1.56) per share of common stock. Net tangible book value per
share represents the amount of our tangible assets less total liabilities,
divided by the number of our outstanding shares of common stock.
Net tangible book value dilution per share represents the difference
between the amount per share paid by purchasers of shares of common stock from
selling stockholders in the offering made hereby and the pro forma net tangible
book value per share of common stock immediately after completion of the
offering. Assuming that the sales of 5,835,771 shares of common stock in the
offering are made at an offering price of $14.78 per share, which is the average
of the high and low sales prices per share of the common stock on July 24, 2003
as reported on The Nasdaq Stock Market, and that we will receive none of the net
proceeds therefrom, the purchasers of common stock from the selling stockholders
would experience an immediate dilution in net tangible book value of $16.34 per
share, as illustrated in the following table:
Assumed public offering price per share.................................. 14.78
Net tangible book value per share as of March 31, 2003 (1).....$(1.56)
Pro forma dilution per share to new investors............................$16.34
-------------------
(1) Because the shares being offered and sold by the selling stockholders are
issued and outstanding and we will receive none of the proceeds from the
offering of the common stock by the selling stockholders, net tangible book
value per share will not change as a result of such offering.
USE OF PROCEEDS
We will not receive any of the proceeds from the sale of the shares of our
common stock by the selling stockholders.
PLAN OF DISTRIBUTION
We are registering under the registration statement of which this
prospectus is a part 5,835,771 shares of our common stock on behalf of the
selling stockholders. These stockholders acquired the shares from an affiliate
of Elan Corporation, plc in private transactions completed in July 2003. The
selling stockholders named in the table below or pledgees, donees, transferees
or other successors in interest selling shares received from a named selling
stockholder as a gift, pledge, partnership distribution or other non-sale
related transfer after the date of this prospectus may sell the shares from time
to time. The selling stockholders will act independently of us in making
decisions regarding the timing, manner and size of each sale.
The securities being offered by this prospectus may be sold by the selling
stockholders on The Nasdaq Stock Market or in the over-the-counter market or
otherwise, at prices and at terms then prevailing or at prices related to the
then-current market price, or in negotiated transactions. The consideration may
be cash or another form of consideration negotiated by the parties. The selling
stockholders may effect these transactions by selling the shares to or through
broker-dealers. The securities may be sold:
o in a block trade in which a broker-dealer will attempt to sell the shares
as agent but may position and resell a portion of the block as principal to
facilitate the transaction,
o in purchases by a broker-dealer as principal and resale by such
broker-dealer for its account under this prospectus,
o in an exchange distribution in accordance with the rules of the respective
exchange,
16
o in ordinary brokerage transactions and transactions in which a broker
solicits purchasers,
o in an over-the-counter distribution in accordance with the rules of The
Nasdaq National Market,
o in privately negotiated transactions directly to purchasers, through a
specific bidding or auction process or otherwise,
o in option transactions, or
o through a combination of any such methods of sale.
To the extent required, this prospectus may be amended or supplemented from
time to time to describe a specific plan of distribution. In effecting sales,
broker-dealers engaged by the selling stockholders may arrange for other
broker-dealers to participate in the resales.
The selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions in connection with distributions
of the shares or otherwise. In connection with these transactions, broker
dealers or other financial institutions may engage in short sales of the shares
in the course of hedging the positions they assume with selling stockholders.
The selling stockholders also may sell shares short and redeliver the shares to
close out such short positions. The selling stockholders may enter into option
or other transactions with broker-dealers which require the delivery to the
broker-dealer of the shares. The broker-dealer may then resell or otherwise
transfer such shares covered by this prospectus (as supplemented or amended to
reflect such transaction). The selling stockholders also may loan or pledge the
shares to a broker-dealer or other financial institution. The broker-dealer may
sell the shares so loaned, or upon a default the broker-dealer may sell the
pledged shares under this prospectus (as supplemented or amended to reflect such
transaction).
Broker-dealers or agents may receive compensation in the form of
commissions, discounts or concessions from selling stockholders. Broker-dealers
or agents may also receive compensation from the purchasers of the shares for
whom they act as agents or to whom they sell as principals, or both.
Compensation as to a particular broker-dealer might be in excess of customary
commissions and will be in amounts to be negotiated in connection with the sale.
Broker-dealers or agents and any other participating broker-dealers or the
selling stockholders may be deemed to be underwriters within the meaning of
Section 2(11) of the Securities Act of 1933, as amended (the "Securities Act"),
in connection with sales of the shares. Accordingly, any such commission,
discount or concession received by them and any profit on the resale of the
shares purchased by them may be deemed to be underwriting discounts or
commissions under the Securities Act. Because selling stockholders may be deemed
to be underwriters within the meaning of Section 2(11) of the Securities Act,
the selling stockholders will be subject to the prospectus delivery requirements
of and statutory liabilities under the Securities Act.
In addition, any securities covered by this prospectus which qualify for
sale in compliance with Rule 144 promulgated under the Securities Act may be
sold under Rule 144 rather than under this prospectus.
The selling stockholders have advised us that they have not entered into
any agreements, understandings or arrangements with any underwriters or
broker-dealers regarding the sale of their securities. There is no underwriter
or coordinating broker acting in connection with the proposed sale of shares by
the selling stockholders.
The shares will be sold only through registered or licensed brokers or
dealers if required under applicable state securities laws. In addition, in
certain states the shares may not be sold unless they have been registered or
qualified for sale in the applicable state or an exemption from the registration
or qualification requirement is available and is complied with.
Under applicable rules and regulations under the Securities Exchange Act of
1934, as amended (the "Exchange Act"), persons engaged in the distribution of
the shares may be limited in their ability to engage in market activities with
respect to such shares. In addition, each selling stockholder will be subject to
applicable PROVISIONS of the Exchange Act and the associated rules and
regulations under the Exchange Act, including Regulation M, which provisions may
limit the timing of purchases and sales of shares of our common stock by the
selling stockholders. We will make copies of this prospectus available to the
selling stockholders and have informed them of the need to deliver copies of
this prospectus to purchasers at or prior to the time of any sale of the shares.
17
We will file a supplement to this prospectus, if required, to comply with
Rule 424(b) under the Securities Act, upon being notified by a selling
stockholder that any material arrangements have been entered into with a
broker-dealer for the sale of shares through a block trade, special offering,
exchange distribution or secondary distribution or a purchase by a broker or
dealer. Such supplement will disclose:
o the name of each such selling stockholder and of the participating
broker-dealer(s),
o the number of shares involved,
o the price at which such shares were sold,
o the commissions paid or discounts or concessions allowed to such
broker-dealer(s), where applicable,
o that such broker-dealer(s) did not conduct any investigation to verify the
information set out or incorporated by reference in this prospectus, and
o other facts material to the transaction.
Agents, underwriters and brokers-dealers may be entitled under agreements
which may be entered into with us to indemnification by us against specified
liabilities, including liabilities incurred under the Securities Act, or to
contribution by us to payments they may be required to make in respect of such
liabilities. If required, a prospectus supplement will describe the terms and
conditions of such indemnification or contribution. Some of the agents,
underwriters or dealers or their affiliates may be customers of, engage in
transactions with or perform services for us or our subsidiaries in the ordinary
course of business.
We will bear all costs, expenses and fees in connection with the
registration of the shares of the selling stockholders, except for the fees and
expenses of counsel or other advisors for the selling stockholders. The selling
stockholders will also bear all commissions and discounts, if any, attributable
to the sales of their shares. The selling stockholders may agree to indemnify
any broker-dealer or agent that participates in transactions involving sales of
the shares against various liabilities, including liabilities arising under the
Securities Act. We have agreed to indemnify each selling stockholder that
received from Elan more than 50,000 shares of our common stock, any underwriter
for such stockholder and any officer or director or person that controls such
stockholder or underwriter against various liabilities in connection with the
offering of the shares, including liabilities arising under the Securities Act.
Each such selling stockholder has agreed to indemnify us, our directors, our
officers who sign the registration statement of which this prospectus is a part,
persons that control us, any underwriter, each other selling stockholder and any
person that controls such underwriter or other selling stockholder against
various liabilities in connection with the offering of the shares, including
liabilities arising under the Securities Act.
We have agreed with selling stockholders that received from Elan more than
50,000 shares of our common stock to keep the registration statement of which
this prospectus constitutes a part effective until the earlier of (i) July 25,
2005, or (ii) such time as all shares covered by this prospectus have been sold
pursuant to and in accordance with the registration statement.
18
SELLING STOCKHOLDERS
The following table sets forth the number of shares owned by each of the
selling stockholders. These stockholders acquired the shares from an affiliate
of Elan Corporation, plc in private transactions completed in July 2003. This
registration statement also shall cover any additional shares of common stock
which become issuable in connection with the shares registered for sale hereby
by reason of any stock dividend, stock split, recapitalization or other similar
transaction effected without the receipt of consideration which results in an
increase in the number of our outstanding shares of common stock.
None of the selling stockholders has had a material relationship with us
within the past three years other than as a result of the ownership of the
shares or other securities of ours.
We do not know when or in what amounts the selling stockholders may offer
shares for sale. The selling stockholders may decide not to sell all or any of
the shares that this prospectus covers. The shares offered by this prospectus
may be offered from time to time by the selling stockholders named below.
Because the selling stockholders may offer all or some of the shares pursuant to
this offering, and because there are currently no agreements, arrangements or
understandings with respect to the sale of any of the shares that the selling
stockholders will hold after completion of the offering, we cannot estimate the
number of shares that the selling stockholders will hold after completion of the
offering.
The percentages of common stock beneficially owned and being offered are
calculated based on 69,267,262 shares of common stock issued and outstanding as
of April 30, 2003.
SHARES OWNED PRIOR
TO THIS OFFERING
---------------------------------------
NUMBER OF SHARES OF
NAME OF PERCENTAGE OF COMMON COMMON STOCK
SELLING STOCKHOLDER NUMBER STOCK OUTSTANDING REGISTERED HEREBY
------------------- ------ --------------------- -----------------
Ardsley Partners Fund II, L.P. 225,000 * 225,000
262 Harbor Drive
4th Floor
Stamford, CT 06902
Ardsley Partners Institutional Fund, 115,000 * 115,000
L.P. 262 Harbor Drive 4th Floor Stamford, CT 06902
Ardsley Offshore Fund, Ltd. 260,000 * 260,000
262 Harbor Drive
4th Floor
Stamford, CT 06902
Citadel Equity Opportunity Investments 350,000 * 350,000
Ltd.
c/o Dundee Leeds Management Services
Ltd.
2nd Floor, Waterfront Centre
28 N. Church Street
George Town, Grand Cayman
Cayman Islands, BWI
19
SHARES OWNED PRIOR
TO THIS OFFERING
---------------------------------------
NUMBER OF SHARES OF
NAME OF PERCENTAGE OF COMMON COMMON STOCK
SELLING STOCKHOLDER NUMBER STOCK OUTSTANDING REGISTERED HEREBY
------------------- ------ --------------------- -----------------
Deerfield Partners, L.P. 2,786,991 4.0 333,008
780 Third Avenue
37th Floor
New York, NY 10017
Deerfield International Limited 2,572,608 3.7 307,392
780 Third Avenue
37th Floor
New York, NY 10017
FrontPoint Healthcare Fund, L.P. 125,000 * 125,000
80 Field Point Road
Greenwich, CT 06830
Goldman, Sachs & Co. 804,671 1.2 804,671
1 New York Plaza
50th Floor
New York, NY 10004
INVESCO Stock Funds, Inc. - INVESCO 100,000 * 100,000
Small Company Growth Fund
4350 South Monaco Street
Denver, CO 80237
Janus Global Life Sciences Fund 3,340,940 4.8 1,500,000
100 Fillmore Street Suite 200
Denver, CO 80206
Maverick Fund USA, Ltd. 185,800 * 185,800
300 Crescent Court
18th Floor
Dallas, TX 75201
Maverick Fund II, Ltd. 93,400 * 93,400
P.O. Box 10658 APO
5th Floor, Harbour Place
George Town, Grand Cayman,
Cayman Islands
Maverick Fund, L.D.C. 420,800 * 420,800
P.O. Box 10658 APO
5th Floor, Harbour Place
George Town, Grand Cayman,
Cayman Islands
20
SHARES OWNED PRIOR
TO THIS OFFERING
---------------------------------------
NUMBER OF SHARES OF
NAME OF PERCENTAGE OF COMMON COMMON STOCK
SELLING STOCKHOLDER NUMBER STOCK OUTSTANDING REGISTERED HEREBY
------------------- ------ --------------------- -----------------
Merlin BioMed Offshore Fund, L.P. 88,000 * 88,000
230 Park Avenue
Suite 928
New York, NY 10169
Merlin BioMed Long-Term Appreciation 12,000 * 12,000
Fund, L.P.
230 Park Avenue
Suite 928
New York, NY 10169
Eaton Vance Variable Trust 6,000 * 6,000
c/o OrbiMed Advisors LLC
767 Third Avenue
30th Floor
New York, NY 10017
Eaton Vance Worldwide Health Sciences 800,000 1.2 800,000
Fund
c/o OrbiMed Advisors LLC
767 Third Avenue
30th Floor
New York, NY 10017
Eaton Vance Emerald Worldwide Health 22,000 * 22,000
Sciences Emerald Fund
c/o OrbiMed Advisors LLC
767 Third Avenue
30th Floor
New York, NY 10017
T. Rowe Price Health Sciences Fund, 225,000 * 50,000
Inc.
c/o T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, Maryland 21202
T. Rowe Price Health Sciences 1,210 * 200
Portfolio, Inc.
c/o T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, Maryland 21202
21
SHARES OWNED PRIOR
TO THIS OFFERING
---------------------------------------
NUMBER OF SHARES OF
NAME OF PERCENTAGE OF COMMON COMMON STOCK
SELLING STOCKHOLDER NUMBER STOCK OUTSTANDING REGISTERED HEREBY
------------------- ------ --------------------- -----------------
TD Mutual Funds - TD Health Sciences 69,101 * 13,600
Fund
c/o T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, Maryland 21202
VALIC Company I - Health Sciences Fund 23,100 * 6,000
c/o T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, Maryland 21202
Manufacturers Investment Trust - 31,400 * 8,700
Health Sciences
c/o T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, Maryland 21202
IDEX Mutual Funds - IDEX - T. Rowe 10,055 * 1,000
Price Health Sciences
c/o T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, Maryland 21202
Raytheon Company Combined DB/DC Master 10,300 * 4,100
Trust - Health Sciences
c/o T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, Maryland 21202
Raytheon Master Pension Trust - Health 14,100 * 4,100
Sciences
c/o T. Rowe Price Associates, Inc.
100 East Pratt Street
Baltimore, Maryland 21202
TOTAL: 12,692,476 5,835,771
========== =========
* Indicates less than 1%
22
LEGAL MATTERS
The validity of the securities offered hereby will be passed upon by
Clifford Chance US LLP, San Diego, California.
EXPERTS
The consolidated financial statements for the years ended December 31,
2002, 2001 and 2000 incorporated in this prospectus by reference from our Annual
Report on Form 10-K for the year ended December 31, 2002 have been audited by
Deloitte & Touche LLP, independent auditors, as stated in their report, which is
incorporated herein by reference (which report expresses an unqualified opinion
and includes an explanatory paragraph referring to a change in accounting
principle), and have been so incorporated in reliance upon the report of such
firm given upon their authority as experts in accounting and auditing.
WE HAVE NOT AUTHORIZED ANY PERSON TO MAKE A STATEMENT THAT DIFFERS FROM WHAT IS
IN THIS PROSPECTUS. IF ANY PERSON DOES MAKE A STATEMENT THAT DIFFERS FROM WHAT
IS IN THIS PROSPECTUS, YOU SHOULD NOT RELY ON IT. THIS PROSPECTUS IS NOT AN
OFFER TO SELL, NOR IS IT AN OFFER TO BUY, THESE SECURITIES IN ANY STATE IN WHICH
THE OFFER OR SALE IS NOT PERMITTED. THE INFORMATION IN THIS PROSPECTUS IS
COMPLETE AND ACCURATE AS OF ITS DATE, BUT THE INFORMATION MAY CHANGE AFTER THAT
DATE.
23
5,835,771 SHARES
LIGAND PHARMACEUTICALS INCORPORATED
COMMON STOCK
----------------------------------
Prospectus
----------------------------------
July 25, 2003
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The following table sets forth all expenses, other than underwriting
discounts and commissions, payable by the registrant in connection with the sale
of the common stock being registered. All the amounts shown are estimates,
except for the SEC registration fee.
SEC registration fee................................. $6,977.84
Printing and engraving expenses...................... 5,000.00
Legal fees and expenses.............................. 15,000.00
Accounting fees and expenses......................... 5,000.00
Transfer agent and registrar fee..................... 30,000.00
Miscellaneous expenses............................... 10,000.00
---------
TOTAL 71,977.84
=========
ITEM 15. INDEMNIFICATION OF OFFICERS AND DIRECTORS.
Under Section 145 of the Delaware General Corporation Law, we have broad
powers to indemnify our officers, directors and third parties acting on our
behalf against liabilities they may incur in such capacities, including
liabilities under the Securities Act.
Our amended and restated certificate of incorporation provides for the
indemnification of all of our officers, directors and third parties acting on
our behalf to the fullest extent permissible under Delaware law.
Our amended and restated by-laws provide for the indemnification of
officers, directors and third parties acting on our behalf if such person acted
in good faith and in a manner reasonably believed to be in and not opposed to
our best interest, and, with respect to any criminal action or proceeding, the
indemnified party had no reason to believe his or her conduct was unlawful.
We maintain directors and officers insurance providing indemnification for
certain of our directors and officers for certain liabilities.
We also entered into indemnification agreements between us and our
directors and officers, which may be sufficiently broad to permit
indemnification of our officers and directors for liabilities arising under the
Securities Act.
Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers or persons controlling us pursuant to
the foregoing provisions, we have been informed that in the opinion of the SEC
such indemnification is against public policy as expressed in the Securities Act
and is therefore unenforceable.
ITEM 16. EXHIBITS.
(A) EXHIBITS.
EXHIBIT NO. DESCRIPTION
4.1 Instruments defining the rights of stockholders.
Reference is made to our Form 8-A registration
statement filed on November 21, 1994 (incorporated
into this registration statement by reference), the
Amended and Restated Certificate of Incorporation
(incorporated into this registration statement by
reference to Exhibit 3.2 to our Form S-4 registration
statement filed on July 9, 1998), the Bylaws
(incorporated into this registration statement by
reference to Exhibit 3.3 of our Form S-4 registration
statement, filed on July 9, 1998), the Amended
Certificate of Designation of Rights, Preferences and
Privileges of Series A Participating Preferred Stock
(incorporated into this registration statement by
reference to Exhibit 3.3 to our quarterly report on
Form 10-Q for the period ended March 31, 1999) and
our Form 8-A registration statement filed on
September 30, 1996, including any amendments or
reports filed for the purposes of updating such
descriptions.
5.1 Opinion of Clifford Chance US LLP
23.1 Consent of Deloitte & Touche LLP, Independent Auditors
23.2 Consent of Clifford Chance US LLP. Included in the Opinion
of Clifford Chance US LLP filed as Exhibit 5.1
24.1 Power of Attorney (See Signature Page on Page II-3).
------------------
II-1
ITEM 17. UNDERTAKINGS.
The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) to include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii) to reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the "Calculation of Registration Fee" table in
the effective registration statement; and
(iii) to include any material information with respect to the plan of
distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement;
(2) That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof;
(3) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the termination of the
offering.
The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plan's annual report pursuant to Section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant
has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer, or controlling person of the registrant in the
successful defense of any action, suit, or proceeding) is asserted by such
director, officer, or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question of whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
II-2
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature
appears below constitutes and appoints David E. Robinson and Paul V. Maier, and
each of them, his or her true and lawful attorneys-in-fact and agents, with full
power of substitution, for him or her and in his or her name, place and stead,
in any and all capacities, to sign any and all amendments (including
post-effective amendments) to this registration statement, and to sign any
registration statement for the same offering covered by this registration
statement that is to be effective upon filing pursuant to Rule 462(b)
promulgated under the Securities Act of 1933, as amended, and all post-effective
amendments thereto, and to file the same, with all exhibits thereto and all
documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents full power and authority to do
and perform each and every act and thing requisite and necessary to be done in
and about the premises, as fully to all intents and purposes as he or she might
or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents, or his or their substitute or substitutes, may
lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, the registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of San Diego, State of California, on July 25, 2003.
LIGAND PHARMACEUTICALS INCORPORATED
By: /S/DAVID E. ROBINSON
-----------------------------
David E. Robinson, President
and Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated:
SIGNATURE TITLE DATE
--------- ----- ----
/S/DAVID E. ROBINSON July 25, 2003
-----------------------------------------
David E. Robinson President and Chief Executive Officer
(Principal Executive Officer)
/S/PAUL V. MAIER July 25, 2003
-----------------------------------------
Paul V. Maier Senior Vice President
and Chief Financial Officer
(Principal Financial and Accounting Officer)
/S/HENRY F. BLISSENBACH July 25, 2003
-----------------------------------------
Henry F. Blissenbach Director
/S/ALEXANDER D. CROSS July 25, 2003
-----------------------------------------
Alexander D. Cross Director
/S/JOHN GROOM July 25, 2003
-----------------------------------------
John Groom Director
/S/IRVING S. JOHNSON July 25, 2003
-----------------------------------------
Irving S. Johnson, Ph.D. Director
-----------------------------------------
John W. Kozarich Director
/S/CARL C. PECK July 25, 2003
-----------------------------------------
Carl C. Peck Director
/S/MICHAEL A. ROCCA July 25, 2003
-----------------------------------------
Michael A. Rocca Director
II-3
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
4.1 Instruments defining the rights of stockholders.
Reference is made to our Form 8-A registration
statement filed on November 21, 1994 (incorporated
into this registration statement by reference), the
Amended and Restated Certificate of Incorporation
(incorporated into this registration statement by
reference to Exhibit 3.2 to our Form S-4 registration
statement filed on July 9, 1998), the Bylaws
(incorporated into this registration statement by
reference to Exhibit 3.3 of our Form S-4 registration
statement, filed on July 9, 1998), the Amended
Certificate of Designation of Rights, Preferences and
Privileges of Series A Participating Preferred Stock
(incorporated into this registration statement by
reference to Exhibit 3.3 to our quarterly report on
Form 10-Q for the period ended March 31, 1999) and
our Form 8-A registration statement filed on
September 30, 1996, including any amendments or
reports filed for the purposes of updating such
descriptions.
5.1 Opinion of Clifford Chance US LLP
23.1 Consent of Deloitte & Touche LLP, Independent Auditors
23.2 Consent of Clifford Chance US LLP. Included in the Opinion
of Clifford Chance US LLP filed as Exhibit 5.1
24.1 Power of Attorney (See Signature Page on Page II-3).
------------------
II-4